ConductScience.org, home

Paper20725732

[New biologics and orally available compounds. What is still in the pipeline?].

Grünke M and 3 others. Z Rheumatol, 2010. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. [New biologics and orally available compounds. What is still in the pipeline?]. Papers, record 20725732. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20725732

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
[New biologics and orally available compounds. What is still in the pipeline?].
PubMed
Journal
Z Rheumatol
PubMed
Year
2010
PubMed
Publication types
English Abstract, Journal Article, Review
PubMed
Citations, by iCite
1
iCite
Relative citation ratio, by iCite
0.03
iCite
Revised in PubMed
2026-10-11
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Grünke MM
2Bastian HH
3Schulze-Koops HH
4Burmester GRG-R

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antirheumatic AgentsMajor topic
Biological ProductsMajor topic
Rheumatic DiseasesMajor topic
RheumatologyMajor topic
Administration, Oral
Humans

References33

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119587388
Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial.
Ann Rheum Dis2010https://conductscience.org/library/papers/19587388PubMed
220065634Denosumab.MAbs2009https://conductscience.org/library/papers/20065634PubMed
311549370Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease.Arthritis Res2001https://conductscience.org/library/papers/11549370PubMed
420391509Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis.Arthritis Care Res (Hoboken)2010https://conductscience.org/library/papers/20391509PubMed
519424068Denosumab update.Curr Opin Rheumatol2009https://conductscience.org/library/papers/19424068PubMed
618438830
Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial.
Arthritis Rheum2008https://conductscience.org/library/papers/18438830PubMed
710632676Exacerbation of acute inflammatory arthritis by the colony-stimulating factors CSF-1 and granulocyte macrophage (GM)-CSF: evidence of macrophage infiltration and local proliferation.Clin Exp Immunol2000https://conductscience.org/library/papers/10632676PubMed
819256507
Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.
J Med Chem2009https://conductscience.org/library/papers/19256507PubMed
916780833The effects of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on T-cell-related cytokine production in vitro and in vivo.Eur J Pharmacol2006https://conductscience.org/library/papers/16780833PubMed
1018551128Colony-stimulating factors in inflammation and autoimmunity.Nat Rev Immunol2008https://conductscience.org/library/papers/18551128PubMed
117932447
Regulation of granulocyte macrophage colony stimulating factor production by human articular chondrocytes. Induction by both tumor necrosis factor-alpha and interleukin 1, downregulation by transforming growth factor beta and upregulation by fibroblast growth factor.
J Rheumatol1994https://conductscience.org/library/papers/7932447PubMed
128049356Evidence for GM-CSF receptor expression in synovial tissue. An analysis by semi-quantitative polymerase chain reaction on rheumatoid arthritis and osteoarthritis synovial biopsies.Eur Cytokine Netw1994https://conductscience.org/library/papers/8049356PubMed
1320506254
Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study.
Arthritis Rheum2010https://conductscience.org/library/papers/20506254PubMed
1419565475
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.
Arthritis Rheum2009https://conductscience.org/library/papers/19565475PubMed
159227165Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice.Ann Rheum Dis1997https://conductscience.org/library/papers/9227165PubMed
1620391513Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients.Arthritis Care Res (Hoboken)2010https://conductscience.org/library/papers/20391513PubMed
1720164774Kinase inhibitors: a new approach to rheumatoid arthritis treatment.Curr Opin Rheumatol2010https://conductscience.org/library/papers/20164774PubMed
1814613291Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator.Arthritis Rheum2003https://conductscience.org/library/papers/14613291PubMed
1917062647Rheumatoid synovial endothelial cells produce macrophage colony-stimulating factor leading to osteoclastogenesis in rheumatoid arthritis.Rheumatology (Oxford)2007https://conductscience.org/library/papers/17062647PubMed
2018975322Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial.Arthritis Rheum2008https://conductscience.org/library/papers/18975322PubMed

See all 33 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn Papers
21590474[Therapeutic strategies in rheumatoid arthritis].Internist (Berl)2011https://conductscience.org/library/papers/21590474

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20725732

GET https://conductscience.org/api/papers/v1/20725732/references?page=2